ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference

Rhea-AI Summary

ImmunoGen, a leader in antibody-drug conjugates for cancer treatment, announced that CFO Susan Altschuller will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on September 28, 2022, at 11:15am ET. A webcast will be available on their website, allowing investors to access the discussion live and later via replay. ImmunoGen is committed to developing targeted therapies that enhance anti-tumor activity while improving patient tolerability, aligning with their mission, TARGET A BETTER NOW™.

Positive

• Participation in a recognized conference may enhance visibility and investor confidence.
• Commitment to developing innovative cancer therapies could lead to improved patient outcomes.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Nantucket Therapeutics Conference. The presentation is scheduled for September 28, 2022 at 11:15am ET.

A webcast of the presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005874/en/

INVESTOR RELATIONS

ImmunoGen

Anabel Chan

781-895-0600

anabel.chan@immunogen.com

MEDIA

ImmunoGen

Courtney O’Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

FAQ

What is the date and time of the ImmunoGen fireside chat at the Guggenheim Nantucket Therapeutics Conference?

The ImmunoGen fireside chat is scheduled for September 28, 2022, at 11:15am ET.

Where can I access the webcast of ImmunoGen's conference presentation?

The webcast of ImmunoGen's conference presentation will be available on their website under the 'Investors and Media' section.

Who is representing ImmunoGen at the Guggenheim Nantucket Therapeutics Conference?

CFO Susan Altschuller will represent ImmunoGen at the conference.

What is ImmunoGen's focus in cancer treatment?

ImmunoGen focuses on developing antibody-drug conjugates to improve outcomes for cancer patients.

What is ImmunoGen's mission statement?

ImmunoGen's mission is encapsulated in their commitment to TARGET A BETTER NOW™.